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Abstract
Background: In a previous study of the Hypertension Genetic Epidemiology Network (HyperGEN) we
have shown that metabolic syndrome (MetS) risk factors were moderately and significantly associated with
echocardiographic (ECHO) left ventricular (LV) phenotypes.
Methods: The study included 1,393 African Americans and 1,133 whites, stratified by type 2 diabetes
mellitus (DM) status. Heritabilities of seven factor scores based on the analysis of 15 traits were sufficiently
high to pursue QTL discovery in this follow-up study.
Results: Three of the QTLs discovered relate to combined MetS-ECHO factors of "blood pressure (BP)-
LV wall thickness" on chromosome 3 at 225 cM with a 2.8 LOD score, on chromosome 20 at 2.1 cM with
a 2.6 LOD score; and for "LV wall thickness" factor on chromosome 16 at 113.5 with a 2.6 LOD score in
whites. The remaining QTLs include one for a "body mass index-insulin (BMI-INS)" factor with a LOD
score of 3.9 on chromosome 2 located at 64.8 cM; one for the same factor on chromosome 12 at 91.4
cM with a 3.3 LOD score; one for a "BP" factor on chromosome 19 located at 67.8 cM with a 3.0 LOD
score. A suggestive linkage was also found for "Lipids-INS" with a 2.7 LOD score located on chromosome
11 at 113.1 cM in African Americans. Of the above QTLs, the one on chromosome 12 for "BMI-INS" is
replicated in both ethnicities, (with highest LOD scores in African Americans). In addition, the QTL for
"LV wall thickness" on chromosome 16q24.2-q24.3 reached its local maximum LOD score at marker
D16S402, which is positioned within the 5th intron of the cadherin 13 gene, implicated in heart and vascular
remodeling.
Conclusion: Our previous study and this follow-up suggest gene loci for some crucial MetS and cardiac
geometry risk factors that contribute to the risk of developing heart disease.
Published: 27 November 2008
BMC Medical Genetics 2008, 9:103 doi:10.1186/1471-2350-9-103
Received: 28 April 2008
Accepted: 27 November 2008
This article is available from: http://www.biomedcentral.com/1471-2350/9/103
© 2008 Kraja et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Medical Genetics 2008, 9:103 http://www.biomedcentral.com/1471-2350/9/103Background
Metabolic Syndrome (MetS), a cluster of obesity, insulin
resistance and glucose intolerance, dyslipidemia, and
high blood pressure, is related to echocardiographic
(ECHO) measurements of the heart. For example, left
ventricular hypertrophy (LVH) is a complex trait that is a
major manifestation of target organ damage in hyperten-
sion [1]. MetS and LVH are reported to increase the risk of
cardiovascular (CV) disease [2-6]. In a recent study we fur-
ther explored the relationships among these traits by uti-
lizing multivariate factor analysis (FA). Correlations
among 15 metabolic and echocardiographic traits ana-
lyzed showed significant relationships among MetS risk
factors (especially systolic and diastolic blood pressure
(BP) and body mass index (BMI)) and cardiac pheno-
types. Factors identified represented new combined MetS-
ECHO domains as for example "BP-LV geometry," and
"BP-LV wall thickness," and also represented known
domains in the MetS such as "BMI-INS," "Lipids-INS,"
"BP," and ECHO domains "LV wall thickness," and "LV
geometry." Quantitative trait loci (QTLs) discovery was
warranted based on the heritability estimates reported [7].
Until recently, different studies have reported QTLs for
MetS or ECHO. Teran-Garcia and Bouchard [8] provide a
comprehensive review of QTLs associated with MetS. In
one of their cited studies, Kraja et al [9] studied QTLs for
MetS factors in the HyperGEN study for two ethnicities. A
QTL with logarithm of odds (LOD) score of 2.8 on chro-
mosome 13p12 for the obesity-INS factor and one with a
LOD of 2.6 on chromosome 11q24 for the lipids-INS fac-
tor were described for African Americans. Also, QTLs for
the BP factor (LOD of 3.2 on chromosome 15q15), for the
lipids-INS factor (a LOD of 3.08 on chromosome 8p23),
and for the obesity-INS factor (LOD of 3.1 on chromo-
some 3p26) were reported in whites. More recently both
linkage and association analysis of ECHO traits have been
reported in the HyperGEN study. Arnett et al [10] study-
ing the LV contractility, reported a LOD of 3.9 at 54 cM on
chromosome 11 in African Americans and a 2.8 LOD
score at 17.9 cM on chromosome 22. Tang et al [11]
reported QTLs for LV early diastolic peak E velocity on
chromosome 5 at 133.6 cM with a LOD of 3.6 in African
Americans, and a LOD score of 2 on chromosome 12 at
105–109 cM for peak A velocity in whites. In the third
paper, Bella et al [12] studied linkage for valve calcifica-
tion finding LOD scores of 3.2 and 2.6 respectively at
105.6 and 130.4 cM on chromosome 16, and a LOD of
2.9 at 48 cM of chromosome 19.
Another recent publication of Mayosi et al [13] performed
genome wide linkage analysis on LV mass of 826 subjects
of British families ascertained for high BP, by selecting the
proband from the top 5% of the population distribution.
They obtained moderate LOD scores (1.5–2.67) for elec-
trocardiographic and echocardiographic LV mass.
The present study extends previous investigations by
focusing concurrently on both MetS risk components and
ECHO phenotypes. In addition, we expect an increase in
power for QTL discovery by utilizing FA factors, because
they capture inter-variable correlations. In this study we
aimed to identify QTLs that control genetic variability of
combined MetS-ECHO factors, as well as individual MetS
and ECHO factor domains in the Hypertension Genetic
Epidemiology Network Study (HyperGEN).
Methods
Subjects
HyperGEN is part of the NHLBI Family Blood Pressure
Program (FBPP), which studies the genetic aspects of high
blood pressure and related conditions [14]. Further
details for the HyperGEN study are provided elsewhere
[7,9-12]. In the current study the focus was on the siblings
and the offspring of the sampled populations. Subjects
with less than 8 hours of fasting time, or missing values
for any of the 15 traits studied were excluded from the
analysis. Consequently, in our study the phenotypes of
1,393 African Americans and of 1,133 Caucasians were
analyzed. The samples were organized also by including/
excluding diabetes mellitus (DM) subjects (for more
details see Huang et al [7]). Clinical data, echocardio-
graphic measurements, questionnaires, and blood sam-
ples were collected with informed consent from the
participants.
Echocardiography
Echocardiograms followed standard protocols as
described by Devereux and Roman [15] to obtain two-
dimensional (2D) guided M-mode, 2D and Doppler
measurements. The measurements were first made by
sonographers or physicians centrally trained at the Read-
ing Center in New York and subsequently verified or
changed by highly experienced cardiologists in the Read-
ing Center, who were blinded to clinical data.
Phenotypic Data
The 15 traits that follow constitute the original traits
which through multivariate factor analyses were trans-
formed into factor scores. The factor scores served as phe-
notypes in our linkage analyses. Fasting glucose (GLUC)
and insulin (INS); triglycerides (TG) and high-density
lipoprotein cholesterol (HDLC); body mass index (BMI);
medication-adjusted systolic and diastolic blood pressure
(SBP and DBP); heart rate (HR), diastolic LV internal
dimension (LVID), posterior wall thickness (PWT) and
relative wall thickness (RWT); LV mass indexed to
height2.7 (LVMI), aortic root diameter (ARD), arterial stiff-
ness defined by pulse pressure/stroke volume (PP/SV),Page 2 of 9
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ate distribution transformations and removal of only a
few outliers to achieve normality. Log transformation was
applied to INS, HDLC, TG, BMI, RWT, LVMI, PWT, and
PP/SV; the reciprocal of squared GLUC (1/GLUC2) and
cubic power transformation for MWS (MWS3) were
applied in both African Americans and whites (see Huang
et al. [7] for details). The SBP and DBP of subjects receiv-
ing anti-hypertensive medication were adjusted for the
anti-hypertensive medication(s) following the method
described by Wu et al. [16] and applied in the HyperGEN
study to estimate untreated BP levels for various classes of
medications. Stepwise regression using the REG proce-
dure of SAS was used for the covariate adjustments for
each of 15 variables, within race and gender by regressing
on age, age2, age3 and field centers, and retaining only the
significant terms. Age and field center effects were
removed from the means and the variances, and standard-
ized residuals were derived. A few outliers beyond ± 4
standard deviations and greater than 1 standard deviation
away from the next internal data point were eliminated.
Final standardized residuals were utilized in the FA. FA is
a multivariate statistical technique which explains varia-
bility of primary variables in terms of fewer unobserved
(latent) variables named factors. The latent factors help to
identify inter-correlations among primary variables. Two
categories of factor analysis, with and without Varimax
rotation, were performed, as previously described [7]. FA
without rotation achieves the simplest factor structure,
where the loading of a variable is maximum with one fac-
tor, associated with little contribution of that variable to
other factors. In contrast, Varimax rotation identifies fac-
tors representing distinct clusters of interrelated variables.
At least two risk variables in a latent factor were required
with loadings of about 0.4 or greater. The factor loadings
were essentially the correlation coefficients between each
original variable and the latent factor. Factor loadings rep-
resent the contribution of each original variable to the
latent factor. The original variables contribution into fac-
tors helped to label each latent factor. The squared factor
loading represented the percentage of variance in the orig-
inal variable associated with the latent factor. The sum of
squared loadings per latent factor had to approach or
exceed one and the maximum likelihood estimate model
was required to be significant (p-value < 0.05). Factor
analysis applied on the 15 normally distributed traits,
produced factor scores which finally were employed in
linkage analyses.
Linkage analysis
The HyperGEN study genotyped 391 microsatellite mark-
ers at the National Heart, Lung, and Blood Institute Mam-
malian Genotyping Service (Marshfield, WI), of which
370 autosomal markers were used for this genome-wide
linkage analysis. Software used to insure the marker' qual-
ity control included ASPEX, GRR, GENEHUNTER and
PEDCHECK [17-19]. The average inter-marker distance
was about 10 centiMorgans (cM). The gender-averaged
genetic distances were retrieved from the Marshfield
human genetic linkage map. Ethnic-specific allele fre-
quencies were calculated based on the random sample
included in the HyperGEN study. Pedigrees were split in
nuclear families for analyses. Multipoint identity by
descent coefficients were estimated with MAPMAKER/
SIBS software, at 1 cM contiguous distances [18]. Finally,
a non-parametric variance component linkage analysis
was performed via SEGPATH software [20]. The non-par-
ametric (or model free) linkage method applied does not
depend on the assumptions about the penetrance of the
phenotype. On the other hand the marker locus model is
applied by hypothesizing an additive effect of a QTL (g),
a residual polygenic component (GR), and a residual non-
familial variance component (r). The null hypothesis of
no linkage was tested by restricting the QTL heritability
(h2g) at the putative locus at h2g = 0. The linkage test
becomes a likelihood ratio of the alternative hypothesis
against the null hypothesis, in every location throughout
the genome where h2g is estimated. This test turns out to
be a χ2 with 1 degree of freedom [20].
Results
Table 1 for the African American's sample is a summary of
LOD scores greater than 1.7 [see also the Additional files
1, 2, 3, 4]. Significant LOD scores greater than or close to
3 were found for "BP" domain in the African American
sample in all data for FA with Varimax rotation (LOD
score of ~3.0, with a peak at 67.8 cM distance on chromo-
some 19). QTLs for "BMI-INS" factor domain were identi-
fied when DM subjects were excluded (LOD of 3.9, at 64.8
cM on chromosome 2, and LOD of 3.3 at 91.4 cM on
chromosome 12). For the same ethnicity, when FA with
NO rotation was applied in all data, the above findings of
chromosomes 2 and 19 replicated with LOD scores
respectively of 2.8 and 2.7. For FA with NO rotation, when
excluding DM participants two peaks for "BMI-INS"
domain replicated above significant LOD scores (on chro-
mosome 2, at 65.8 cM, LOD of 3.6, and on chromosome
12, at 91.4 cM, LOD of 3.2).
Table 2 is a summary of QTL findings for the white sample
[see also the Additional files 5, 6, 7, 8]. The "BP-LV wall
thickness" factor, a combination of MetS-ECHO domains,
result of FA with NO rotation when excluding DM sub-
jects in whites, showed suggestive linkage with a maxi-
mum peak of 2.8 LOD score on chromosome 3 at 224.9
cM, and a 2.6 LOD score on chromosome 20 at 2.1 cM. In
addition, in the same ethnicity, for the "LV wall thickness"
factor domain, two suggestive peaks were found; one on
chromosome 3 at 114.3 cM, with LOD score of 2.7 for all
data and NO rotation, and one on chromosome 16 atPage 3 of 9
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imax rotation and excluding DM subjects.
Discussion
In the present study we examined a group of latent factors
identified by performing factor analyses on 15 MetS or
ECHO traits. The seven identified latent factors reduced
the complexity of this large number of phenotypes. "Lip-
ids-INS" factor was mainly contributed to by HLDC, TG
and INS. "BMI-INS" was another factor identified from
MetS domains. From the ECHO variables two latent fac-
tors were identified, "LV wall thickness" with main contri-
butions from LVMI, PWT, RWT and MWS, and "LV
geometry" with main contributors LVMI, LVID and RWT.
"BP" factor, primarily a combination of SBP and DBP, was
strongly evidenced in African Americans. However, when
factor analysis with no rotation was applied in the whites,
BP combined with "LV wall thickness" and "LV geometry"
to form two new latent variables "BP-LV geometry" a com-
bination of SBP, DBP, LVMI, PWT and LVID and "BP-LV
dimension wall thickness" a combination of SBP, DBP,
LVID, RWT and PP/SV. We look at these factors as MetS,
ECHO, and a combination of MetS-ECHO latent factors.
The presence of BP as a connector between MetS and
ECHO is consistent with the increased risk of CV disease
associated with hypertension. Chinali et al [21] found
that abnormal LV geometry and function are related to the
MetS, with increased BP being the MetS component most
strongly associated with cardiac abnormalities [22].
Therefore, combined MetS-ECHO domains with BP con-
tributions in the HyperGEN whites extend previous find-
ings.
Two QTLs, one from MetS domains, and one from ECHO
were prominent. The chromosome 12 QTL for the "BMI-
INS" factor was replicated across ethnic groups, although
the LOD scores were larger in African Americans. Its loca-
tion coincides with linkage reports at 12q24.2 for non-
Table 1: Major QTL findings per chromosome, LOD > 1.7 in African Americans
No Rotation Excluding DM Chromosome Sex-averaged distance 
in cM, peak and 
(surrounding markers)
Marker name Dname LOD* Score Factor Domain
1 NO NO 2 68.76 (64.29–73.61) ATA4F03-
ATA27D04
D2S1356-
D2S1352
2.84 BMI-INS
2 12 100.42 (95.03–104.12) GATA63D12-
GATA85A04
D12S1064-
D12S1300
1.98 BMI-INS
3 19 68.84 (68.08) MDF139 D19S178 2.67 BP
4 20 4.13 (2.13) AFM077XD3 D20S103 1.78 BMI-INS
5 NO YES 2 49.76 (47.97–55.51) GATA8F07-
GATA86E02
D2S405-D2S1788 2.41 BMI-INS
6 2 65.76 (64.29–73.61) ATA4F03-
ATA27D04
D2S1356-
D2S1352
3.62 BMI-INS
7 5 114 (114.75) ATA4D10 D5S1453 2.36 BP
8 11 91.11 (85.48–100.82) GATA30G01-
GATA28D01
D11S2002-
D11S2000
1.80 BMI-INS
9 12 91.42 (83.19–95.03) GATA26D02-
GATA63D12
D12S1052-
D12S1064
3.22 BMI-INS
10 18 54.84 (54.40) GATA64H04 D18S877 2.37 BMI-INS
11 19 70.84 (68.08–78.08) MFD139-MFD232 D19S178-
D19S246
2.18 BP
12 VAR† NO 5 36.00 (36.25) GATA134B03 D5S2845 2.42 LIPIDS-INS
13 10 153.32 
(148.17–165.27)
GGAA5D10-
GGAA23C05
D10S1213-
D10S1248
1.87 LIPIDS-INS
14 11 113.11 (113.13) GATA23606 D11S1998 2.66 LIPIDS-INS
15 19 67.84 (68.08) MFD139 D19S178 2.97 BP
16 VAR YES 2 64.76 (64.29) ATA4F03 D2S1356 3.90 BMI-INS
17 5 115.00 (115.75) ATA4D10 D5S1453 2.02 BP
18 12 91.42 (83.19–95.03) GATA26D02-
GATA63D12
D12S1052-
D12S1064
3.34 BMI-INS
19 18 54.84 (54.40) GATA64H04 D18S877 2.02 BMI-INS
20 19 68.84 (68.08) MFD139 D19S178 1.98 BP
* Logarithm of odds; †Varimax rotationPage 4 of 9
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ple sclerosis [23,24]. In this area the ACACB gene located
on 12q24.1 may be a candidate. This gene reported in
murine studies, has been implicated in controlling mito-
chondrial fat oxidation and is considered a regulator of
energy expenditure [25]. Although Wilson et al [26]
reported a finding for fat mass in 12q24, their peak loca-
tion is about 30–35 cM apart from our "BMI-INS" peak
finding.
Of particular note are the results in the region around the
marker AFM031XA5 (D16S402) at 16q24.2-q24.3 for the
"LV wall thickness" in whites. This location marked by
D16S402, has been found to be linked with cadherin 13
(CDH13) gene. CDH13, which is also called heart cad-
herin, is believed to be a calcium dependent mediator of
cell-cell interaction in the heart and acts as negative regu-
lator of neural cell growth. Joshi et al [27] claimed cad-
herin may have multiple signaling functions in vascular
remodeling and may protect endothelial cells from oxida-
tive stress-induced apoptosis. The CDH13 gene is about
1.2 M bp long, has 14 exons and encodes for a protein
with 713 amino acids. This gene is most highly expressed
in the heart. The AFM031XA5 marker represents a
sequence between 81,851,181–81,851,356 (bp), pre-
cisely in the non-coding 5th intronic region. We hypothe-
size that the CDH13 polymorphism, involved in calcium
mediated cell-cell adhesion, can influence calcium depo-
sition in the heart. Such a hypothesis is supported also by
the Bella et al [12] study of valve calcification in the
HyperGEN where a significant QTL (3.2 LOD score) was
located on chromosome 16 relatively close to the above
marker. In contrast, Mayosi et al [13] findings on chromo-
some 12 and 16 on LV mass do not overlap with our find-
ings. We have a putative QTL located at 47 cM (1.99 LOD
score) on chromosome 12 for LV Geometry factor (with
Table 2: Major QTL findings per chromosome, LOD > 1.7 in whites
No Rotation Excluding DM Chromosome Sex-averaged distance in 
cM, peak and 
(surrounding markers)
Marker name Dname LOD* Score Factor Domain
1 NO NO 3 114.32 (112.42) GATA128C02 D3S4529 2.71 LV WALL 
THICKNESS
2 16 113.46 (113.52) AFM031XA5 D16S402 1.79 LV WALL 
THICKNESS
3 20 4.13 (2.13) AFM077XD3 D20S103 1.82 BP-LV WALL 
THICKNESS
4 NO YES 3 201.32 (201.14) AFM059XA9 D3S1262 1.98 BP-LV GEOMETRY
5 3 224.88 AFM254VE1 D3S1311 2.79 BP-LV WALL 
THICKNESS
6 12 98.42 (95.03) GATA63D12 D12S1064 2.32 BMI-INS
7 15 78.30 (82.84) ATA28G05 D15S655 1.90 LV WALL 
THICKNESS
8 16 113.46 (113.52) AFM031XA5 D16S402 2.61 LV WALL 
THICKNESS
9 20 2.13 AFM077XD3 D20S103 2.61 BP-LV WALL 
THICKNESS
10 VAR† NO 3 5.32 (5.54) GATA22G12 D3S2387 2.01 BMI-INS
11 3 114.32 (112.42) GATA128C02 D3S4529 2.18 LV WALL 
THICKNESS
12 11 17.11 (8.9) ATA33B03 D11S2362 1.81 BMI-INS
13 12 47.42 (48.7) ATA27A06 D12S1042 1.99 LV GEOMETRY
14 16 113.46 (113.52) AFM031XA5 D16S402 1.72 LV WALL 
THICKNESS
15 21 19.99 (24.73) GATA129D11 D21S2052 1.81 LV WALL 
THICKNESS
16 VAR YES 3 218.32 (215.84) ATA22E01 D3S2418 2.26 LV GEOMETRY
17 11 28.11 (33.02) ATA34E08 UNKNOWN 1.72 BMI-INS
18 12 87.42 (95.03) GATA63D12 D12S1064 2.00 BMI-INS
19 14 107.46 (105.53) GGAA21G11 D14S617 1.87 BP
20 16 113.46 (113.52) AFM031XA5 D16S402 2.81 LV WALL 
THICKNESS
* Logarithm of odds; †Varimax rotationPage 5 of 9
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whites. Theirs, (2.19 LOD score) is located at 75 cM based
on the Marshfield genetic map. Our finding on chromo-
some 16 for LV wall thickness in whites (with contribu-
tions of LVID (+), RWT (+), and LVMI (+)) reaches a local
maximum of 2.81 LOD score at 113 cM. Theirs is located
at the start of chromosome 16 (18.07 cM based on the
Marshfield map), and reached a local maximum of 1.85
LOD score. Such differences may arise for several reasons;
our study is ascertained for hypertension [14], larger in
sample, our factor scores are composite traits compared to
theirs for LV mass, to mention a few.
Other genetic linkage findings of interest included the
MetS and ECHO factors, for "BP-LV wall thickness" and
"BP-LV geometry" in whites (Table 2). For the "BP-LV
geometry" factor a QTL on chromosome 3 at marker
D3S1262 (201.3 cM) showed a LOD of 2.0 in the same
location where an abdominal obesity MetS QTL was
reported. [28] A QTL for "BP-LV wall thickness" factor
with peak LOD score of 2.8 located on marker D3S1311
(225 cM), in proximity to DLG1 gene which is reported to
have a role in the epithelial differentiation and regulation
of smooth muscle [29,30]. A LOD score of 2.3 was found
for "LV geometry" after Varimax rotation, in a region that
includes the FGF12 gene (fibroblast growth factor 12)
which binds to the C terminus of the cardiac voltage-gated
sodium channel Na(v)1.5 and modulates the properties
of the channel [31].
MetS related factors showed potentially important QTLs
for African Americans. For example, "BMI-INS" factor
showed highly significant results on 2p22-2p21 and on
12q24.2, as did the "BP" factor on 19q13.1 (Table 1).
Chen et al [32] have previously reported strong linkage
evidence in West Africans for percent body fat on chromo-
some 2 at 72.6 cM, relatively close to our 2p22-2p21 QTL
finding. A possible candidate gene located at 2p21, close
to the position of our linkage markers, is the LSL gene,
which controls leptin serum levels. Candidate regions
linking to our chromosome 19 BP QTL region have also
been reported as for example by Bielinski et al. [33] for
pulse pressure. Also Cooper et al [34] described an SBP
QTL for Nigerians marked with D19S246 at 78.1 cM
(about 7 cM distant from our finding) on the Marshfield
map. Finally, in our study LOD scores increased when
excluding DM subjects, which can be a reflection of the
effect of genetic heterogeneity caused by diabetes.
Our new findings differ in several regards with the previ-
ous analysis of MetS in the HyperGEN study [9]. First, the
majority of the selected risk factors differ. The previous
study had 11 risk variables to characterize only MetS;
while the current one includes MetS variables and varia-
bles that additionally embrace cardiac geometry and func-
tion. Second, the sample sizes are not the same, and vary
because of elimination due to missing values per variable
and inability to include subjects from the 5th HyperGEN
center that did not participate in the ECHO study. Third,
only 50–57% of the total original risk factors' variance
was explained by the latent factors accepted in the model.
Finally, the identified factors differ across studies in terms
of the contribution of specific risk factors. Nevertheless
when it comes to the "Lipids-INS" factor, (where a key
contribution in African Americans was from HDLC, TG,
and INS), the suggestive QTL found in the previous study
on chromosome 11q24, is replicated in this study with a
similar LOD score, but with a shift of the peak location
(from 131.3 cM to 113.1 cM). Combined traits analysis
can discover QTL locations that affect more than one trait,
i.e. with pleiotropic effects. The 11q23-24 human genome
location is well known for a cluster of genes (APOA1,
APOC3, APOA4, and APOA5), which effect the lipid levels
as well as is associated with DM and heart disease [35]. In
contrast, the use of two methodologies with and without
Varimax rotation it might artificially increase the chances
to obtain significant linkage results. Rao and Gu [36]
showed that for a set of 400 genome wide markers, if the
LOD score threshold is relaxed to ~1.75, one expects a tol-
erance of 1 false-positive per genome. It is expected that
this threshold, used by us in reporting results, may achieve
a better "balance" of the types of the statistical errors.
However, in this study we emphasized LOD score results
at the level of above 2.5 and 3. Also the arrangements of
risk factors into MetS (and ECHO) factors lessen multiple
comparison issues [37]. Another problem is the fact that
we did not have a full evidence of replication about the
QTLs in African-Americans and whites. Hirschhorn et al
[38] have shown through simulations that a QTL explain-
ing 20% of variance can produce strong signal in one link-
age analysis, but it can be undetectable in another one,
simply for the reason of sampling variation. An additional
possibility is that a common causal genetic mutation in
one population might be rare in another population.
We expected not only that factor scores to provide an
opportunity to detect pleiotropic gene effects. In addition,
when traits closely related such as SBP and DBP form a
separate factor they provide an increased power to detect
putative QTLs compared with single trait analysis. For
example, analyzing separately SBP and DBP produced
weak LOD scores in the peak found on chromosome 19.
When analyzed with the factor scores in African Ameri-
cans we found a LOD score of 2.67, 2.18, 2.97, and 1.98
depending on the rotation method used and including or
excluding T2D subjects. Nevertheless we do not know if
the BP factor findings are true or type I error results. Con-
sequently, further elucidation of the precise location of
the causative polymorphisms of the identified linkagePage 6 of 9
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SNPs.
Conclusion
This study is the first genome-wide linkage study that uti-
lizes factors scores derived simultaneously both from
domains of MetS and of cardiac geometric and function-
ality phenotypes. They provide some insight into the
genetic relationship underlying MetS and cardiovascular
traits. Refined SNPs genotyping with a million SNPs plat-
form will soon enhance the ability to discover causative
genes of the cardiac- and MetS related QTLs on chromo-
some 16q24.2-q24.3 that coincided with linkage within
cadherin 13 gene and the one on 12q24 which replicated
in both ethnicities.
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